(-)Deprenyl in the treatment of decompensated Parkinson's disease

J Neural Transm Suppl. 1986:22:247-52.

Abstract

Two main forms of declining motor performance are evident in Parkinson's disease: response fluctuations and "loss of benefit", i.e., the progression of the disease without "on-off" symptoms. (-)Deprenyl has a favourable beneficial effect in reducing the mild forms of response fluctuations. The addition of (-)deprenyl in such patients to the continuing substitution therapy prevents the development of more severe "on-off" manifestations. In severely disabled patients with irregular response swings or permanent akinesia the use of (-)deprenyl as an adjuvant drug cannot modify anymore the course of the disease.

MeSH terms

  • Benserazide / therapeutic use*
  • Drug Combinations / therapeutic use
  • Humans
  • Hydrazines / therapeutic use*
  • Levodopa / therapeutic use*
  • Movement Disorders / drug therapy*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology
  • Phenethylamines / therapeutic use*
  • Selegiline / therapeutic use*

Substances

  • Drug Combinations
  • Hydrazines
  • Phenethylamines
  • benserazide, levodopa drug combination
  • Selegiline
  • Levodopa
  • Benserazide